Five patients with advanced breast cancer were treated with pooled dialyzable transfer factor from healthy adult donors. The period of treatment ranged from 21 to 310 days, the total dose from 20 to 257 ml. Transfer factor did not elicit inflammatory or hypersensitivity reactions or detectable formation of antibody to itself, nor any hematological or biochemical abnormalities or other side effects. Three patients became responsive (by skin test) to tuberculin and/or streptococcal antigens. Marked partial regression of the breast cancer, lasting 6 months, was observed in one patient.
One of the immunological methods that have been considered in the context of cancer therapy is the transfer of immunity with lymphocytes or lymphocyte extracts from deliberately immunized donors or from donors suspected of being resistant to the type of cancer in question. There are reports that laboratory animals with established tumor grafts can be successfully treated by transferring large numbers of lymphocytes from tumor-immunized syngeneic, allogeneic, or xenogeneic donors (1, 2). Human cancer patients have been treated with blood leukocytes from other cancer patients who had been inoculated with the recipients' tumor tissue (3) . This was rarely effective. Because of possible risks associated with inoculating cancer cells into patients, and because of severe reactions produced by large numbers of foreign lymphocytes, we have used a procedure that does not involve deliberate immunization, and that does not provoke untoward reactions.
Our approach was prompted by (a) Thomas' suggestion of the evolutionary significance of cellular immunity as a defense against neoplasia (4) , a homoiostatic function that Burnet termed immunologic surveillance (5) ; and (b) by increasing evidence that established dialyzable transfer factor (TFd) as a potent immunologic agent that reconstitutes cellular immunity in patients with a variety of congenital (6, 7) and acquired (8-11) cellular immunodeficiency syndromes and with cancer (12) . TFd has also proved effective in restoring cellular immunity in patients with mucocutaneous candidiasis (7, (13) (14) (15) and disseminated coccidiomycosis (16) , and this has had a beneficial effect on the outcome of these infections.
We report here attempts at immunologic reconstitution of five patients with advanced breast cancer. We used pooled TFd collected and prepared from blood leukocytes of normal women over 40 years of age. The basic assumption was that healthy women in this age group have eliminated incipient (17) .
METHODS
Blood was collected from healthy women, age 40-65 years, who had no history of cancer or hepatitis. Blood (375 ml) was drawn into an Ion Exchange Pack (JB-2, Fenwal Laboratories, Morton Grove, Ill.), 130 ml of 6% Dextran in saline (Grade H, Pharmachem Corp., Bethlehem, Pa.) was added, and the erythrocytes were allowed to settle for 1 hr at 37°. The supernatant plasma and leukocytes were then removed with a plasma extractor into a transfer pack (TA-2, Fenwal Laboratories) and centrifuged in the pack at 2400 rpm (1200 X g) in a refrigerated centrifuge (International PR2). All but 30-50 ml of the supernatant were removed, and the leukocytes mixed with the remaining plasma were then transferred into sterile centrifuge tubes in 8-ml aliquots and centrifuged at 1800 rpm (650 X g) for 30 min. The supernatant was removed, and a few drops of saline were added to the packed leukocytes, which were then transferred into glass vials and stored at -70°. The yield from one blood donation was 0.5-5.0 ml of packed leukocytes, including no more than 1.0 ml of saline.
For the preparation of TFd, Candida antigen (Hollister Stier Laboratories, Yeadon, Pa.). SH antigen and SH antibodies were assayed by hemagglutination inhibition and hemagglutination, respectively. The immunoglobulin concentration in the serum was measured by radial immunodiffusion on Immuno-Plates (Hyland Division, Travenol Laboratories, Inc., Los Angeles, Calif.).
RESULTS

Properties of TFd preparations
The results of chemical analysis of three batches of TFd are summarized in Table 1 . A fair degree of uniformity is evident, the mean being 2536 mg of total solids, 698 mg of biuret-positive material, and 146 mg of nitrogen for each 100 ml of leukocyte concentrate. Fig. 1 shows the results of spectrophotometric analysis of three of these batches. The absorbancy peak was at 253 nm in each case.
Case histories B.B., a 59-year-old Negro woman, underwent left radical mastectomy on 23 July 1965 for infiltrating duct carcinoma, grade III, metastatic to axillary nodes at levels 1 and 2, followed by treatment with ThioTepa. In August 1966, recurrent disease of the chest wall was noted and irradiated with 5000 rads. In December 1966, the patient noted rapidly increasing redness of the skin and heaviness of the right breast. The clinical diagnosis of inflammatory carcinoma was confirmed by biopsy. The patient was treated with TFd from 21 February 1967 to 10 January 1968. She received a total dose of 257 ml in 310 days (Fig. 2) . Three weeks after the beginning of treatment, the tumor in the right breast became softer and smaller, the edge of the involved area of the skin receded, and the erythema was replaced by dark pigmentation. The skin, which had been distended and tense, could now be wrinkled easily, and the patient felt great relief and was once again able to sleep on her right side. This state of partial tumor regression was maintained for 6 months. Then, the tumor started to grow again and could no longer be controlled by treatment with TFd (later batches of TFd were prepared from the leukocytes of different donors). Subsequent hypophysectomy, radiation therapy, and chemotherapy with 5-fluorouracil'had no beneficial effect, and the patient expired on 18 July 1968 with progressive metastatic disease.
RX., a 40-year-old Puerto Rican woman, was first seen in in 1963 at another hospital with apparently inoperable carcinoma of the left breast. She was treated with radiation (5000 rads to left breast, supraclavicular area, and axilla), Methotrexate, and ThioTepa; she also received radiation (2000 rads) to her ovaries, which resulted in amenorrhoea. After another course of radiation therapy (2200 rads) to the left breast, palliation was attempted by simple mastectomy in July 1965 (widely infiltrating duct carcinoma, grade III, with invasion of lymphatics and metastases to multiple axillary lymph nodes), followed by radiation therapy (4200 rads) to the left supraclavicular area. In July 1966, more radiation therapy was given to the left side of the chest and the right axilla. In May 1967; the patient presented with inflammatory carcinoma (confirmed by biopsy) involving the right breast, right axilla, and entire left side of the chest. TFd was given from 12 May to 28 September, a total dose of 162 ml. Initially, some flattening and softening of the margins of the involved skin were noted, and the patient felt pain in this area several hours after the injections. There tumor regression, however, and eventually the disease progressed. Subsequently, the patient was treated with 5-fluorouracil, Chlorambucil, arabinosylcytosine, -asparaginase, hypophysectomy, Medrogestone, radiation therapy, and phenylalanine mustard. While none of these measures induced regression of the tumor, it grew very slowly; the patient died in December, 1970. Three other patients received injections of 20 ml, 46.5 ml, and 48 ml of TFd. This treatment did not alter the course of their disease.
Histological Findings. Ten biopsy specimens obtained at various times during therapy were compared with pretreatment specimens in patient B.B. Considerable infiltrates of lymphocytes and plasma cells surrounding nests of cancer cells were present before therpay, and this did not change during treatment.
Transfer of Delayed Hypersensitivity to Microbial Antigen. The first TFd preparation given to patient B.B. was prepared from the leukocytes of only one donor (in contrast to all preparations used later) who was known to react strongly to PPD and SK/SD but not to coccidiodin or diphtheria toxoid. In this instance, the skin tests were performed 6 hr after the injection of TFd. Both local and systemic transfer of sensitivity to PPD and SK/SD had occurred at that time, while skin reactions to diphtheria toxoid or coccidioidin could not be elicited. Although the donors whose leukocytes constituted the various pools were not tested, it was assumed that most of them were sensitive to SK/SD, and some to PPD. When we consider the large amount of TFd given, and the large number of individual donors in each pool, it seems likely that each patient received components that effect transfer of sensitivity to SK/SD, and possibly PPD, in healthy recipients. The results of skin tests are summarized in Table 2 specificity for the antigens of the tumor in question with the intent of transferring tumor-specific immunity, (ii) to use TFd of undetermined specificity in an effort to restore cellular immunity in general, and (iii) to use pooled TFd from many donors assuming that it may serve both purposes. We have assessed options two and three. Our experience has shown that TFd can be given with impunity to cancer patients in large amounts over long periods of time. The complete absence of side effects is noteworthy and contrasts with fever and hypersensitivity reactions that are seen when viable leukocytes or homogenates of leukocytes are administered in similar amounts. Moreover, the risk of a graft-versus-host reaction in cancer patients whose cellular immune mechanism is frequently impaired, is eliminated. Evidently, the administration of TFd is limited only by the availability of the leukocytes from which it is obtained. In addition to the absence of immediate side effects, it is noteworthy that hepatitis was not transmitted; there is, in fact, no reported instance of transmission of hepatitis with TFd. This and the lack of sensitization to leukocyte antigens was also borne out by serological studies.
Although causing no toxic effects, TFd was effective in transferring delayed hypersensitivity to patients with advanced cancer. That transfer of sensitivity to tuberculin and streptococcal antigens was not achieved in every case may have been due to the critical condition of some recipients (one patient was moribund when treatment was started) or to differences in the distribution of specificity in different pools.
After our initial investigation of pooled TFd (17) (20, 21) or sarcoma (22, 23) , or from healthy unrelated individuals who were known to have responded immunologically to antigens that were also found in association with a certain type of cancer (24) . In the latter case, the recipients of TFd were patients with nasopharyngeal carcinoma, and the donors were individuals who had recovered from infectious mononucleosis, two diseases that are associated with high titers of antibodies to the Epstein-Barr virus in the serum (25, 26) . Inflammatory reactions in tumor tissue, partial tumor regression, and the development of immunological reactivity to tumor antigens were observed in some cases. While these observations are of considerable interest, it has to be kept in mind that the specificity of tumor-associated immune reactions in these circumstances is still far from clear, and that transfer of cellular immunity to cancer-specific antigens of the cell surface (which make cells vulnerable to immunological attack) has not yet been proved.
We do not suggest, at this point, that pooled TFd from healthy donors offers promise in the treatment of patients with breast cancer or any other type of cancer; an impressive response was seen in only one of five of these patients. It was, in fact, the concern that premature hopes might be raised that restrained us from reporting our experience at an earlier date. We feel, however, that publication is now both justified and timely, since TFd is being used on such a wide scale to treat patients with a variety of syndromes that result from immunological deficiency. For physicians who treat such syndromes it is important to know that large amounts of TFd can be given over long periods without risk to their patients. Moreover 
